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The data presented here support the research article “Association
of serum mimecan with angiographic coronary collateralization in
patients with stable coronary artery disease and chronic total
occlusion” (Shen et al., 2016) [1] where elevated circulating
mimecan levels reﬂected poor angiographic coronary collater-
alization in such patients. The data included in this article are
composed by one ﬁgure and consist of (1) validation of serum
mimecan measurement by assessing inter- and intra-assay varia-
bility in 45 samples; (2) ﬁndings on the relation of clinical and
angiographic characteristics and biochemical parameters to cor-
onary collateralization in 559 patients; (3) the diagnostic value of
serum mimecan for poor collateralization, which was derived from
plotting receiver-operating characteristic curves and logistic
regression analysis.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
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iology, Rui Jin Hospital, Jiaotong University School of Medicine, Shanghai
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 Data on low coronary collateralization in stable angina patients who have concurrently elevated
circulating mimecan levels are suited for studies investigating the mechanism of collateral
development.
 The data provide a novel biomarker of poor collateral formation which may be instrumental in
further studies on risk stratiﬁcation and cardiovascular outcome particularly for patients with
chronic coronary total occlusion.
 The multivariable data involving clinical, biochemical, and angiographic parameters provide
opportunities for the application of advanced approaches in an integrity way, potentially leading to
new insight on the pathophysiology of coronary artery disease.1. Data
The data consist of clinical characteristics and angiographic features along with biochemical
measurements associated with coronary collateralization in patients with stable angina and chronic
total occlusion, and the results of multivariable logistic regression analysis for diagnostic value of
serum mimecan in detecting poor collateralization. The data also include the coefﬁcient of variance
for serum mimecan assay [1].2. Experimental design, material and methods
2.1. Study population
The data included a cohort of 648 consecutive patients with stable angina and chronic total
occlusion (43 months) of at least one major epicardial coronary artery. The participants were pro-
spectively entered a database [2]. Information on patient demographics, clinical and angiographic
feature and in-hospital management was collected retrospectively, whereas clinical outcome during
follow-up was identiﬁed prospectively. For the purpose of the study that the data are based on, 89
patients were excluded by the exclusion criteria, and 559 patients were eligible for ﬁnal analysis (Fig. 1).
Fig. 1. Flowchart of patient enrollment.
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Coronary angiography ﬁlms were reviewed by two experienced cardiologists blinded to the
clinical and demographic data of all patients. Any differences in interpretation were resolved by a
third reviewer who was blinded to the reading of the ﬁrst two reviewers. The presence and sig-
niﬁcance of collaterals ﬁlling from the contra-lateral vessel were graded on the Rentrop scoring
system according to visibility and ﬁlling characteristics [3]. Rentrop score of 0 and 1 was classiﬁed as
poor collateralization and Rentrop score of 2 and 3 as good collateralization [4,5].
2.3. Mimecan measurement
Blood samples taken at the day of angiography were transferred immediately into pyrogen-free
tubes containing EDTA-2Na (1 mg/ml) and then centrifuged immediately at 1500g for 15 min. The
resulting plasma samples were stored frozen at 80 °C in multiple aliquots until analysis. A com-
mercially available ELISA kit (Antibodies-online Inc., Atlanta, GA, USA) was used for determination of
mimecan levels. To assess the accuracy of serum mimecan measurement, inter-assay variability was
made by calculating the coefﬁcient of variance (CV¼standard deviation/mean100) of 4 replicate
measurements of each 15 samples from tertiles of mimecan, and intra-assay variability was assessed
by calculating the CV of 2 replicate for 45 samples.
2.4. Statistical analysis
All analyses were performed with the SPSS 20.0 for Windows (SPSS, Inc., Chicago, IL, USA). Con-
tinuous and categorical data are presented as mean and standard deviation (SD) or median (inter-
quartile range [IQR]) and frequencies or percentages, and statistical difference between groups was
evaluated with the student t-test and chi-square test, respectively. Correlation between serum
mimecan and Rentrop scores was determined by the Spearman's rho test. Multivariable logistic
regression analysis was performed to assess the independent determinants of poor collateralization.
In model 1, conventional clinical, biochemical and angiographic variables were include, and in model
Y. Shen et al. / Data in Brief 9 (2016) 585–5885882, serum level of mimecan (per SD) was additionally included as well as the variables in model 1.
Receiver-operating characteristic curves were plotted with the predicted probabilities for poor col-
lateralization derived from logistic regression models. The C statistics were compared using DeLong
method, and net reclassiﬁcation improvement (NRI) and integrated discrimination improvement (IDI)
of the addition of mimecan in model 2 were calculated to assess predictive performance improve-
ment [6]. A po0.05 was considered to be statistically signiﬁcant.Acknowledgments
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